KR20230008742A - (9r,135s)-13-{4-[5-클로로-2-(4-클로로-1h,2,3-트리아졸-1-일)페닐]-6-옥소-1,6-디히드로피리미딘-1-일}-3-(디플루오로메틸)-9-메틸-3,4,7,15-테트라아자트리시클로[12.3.1.02·6]옥타데카-1(18),2(6),4,14,16-펜타엔-8-온의 결정질 형태 - Google Patents

(9r,135s)-13-{4-[5-클로로-2-(4-클로로-1h,2,3-트리아졸-1-일)페닐]-6-옥소-1,6-디히드로피리미딘-1-일}-3-(디플루오로메틸)-9-메틸-3,4,7,15-테트라아자트리시클로[12.3.1.02·6]옥타데카-1(18),2(6),4,14,16-펜타엔-8-온의 결정질 형태 Download PDF

Info

Publication number
KR20230008742A
KR20230008742A KR1020227039277A KR20227039277A KR20230008742A KR 20230008742 A KR20230008742 A KR 20230008742A KR 1020227039277 A KR1020227039277 A KR 1020227039277A KR 20227039277 A KR20227039277 A KR 20227039277A KR 20230008742 A KR20230008742 A KR 20230008742A
Authority
KR
South Korea
Prior art keywords
crystalline form
compound
spectrum
infrared
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227039277A
Other languages
English (en)
Korean (ko)
Inventor
앤드류 케이. 딜거
마이클 에이. 갈렐라
다니엘 스미스
테레사 엠. 지엠바
다비드 뤼데커
크리스토스 시오우라스
디팔리 아후자
더크 안젤리나 제이. 클리렌
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니, 얀센 파마슈티카 엔.브이. filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20230008742A publication Critical patent/KR20230008742A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020227039277A 2020-04-10 2021-04-09 (9r,135s)-13-{4-[5-클로로-2-(4-클로로-1h,2,3-트리아졸-1-일)페닐]-6-옥소-1,6-디히드로피리미딘-1-일}-3-(디플루오로메틸)-9-메틸-3,4,7,15-테트라아자트리시클로[12.3.1.02·6]옥타데카-1(18),2(6),4,14,16-펜타엔-8-온의 결정질 형태 Pending KR20230008742A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063008161P 2020-04-10 2020-04-10
US63/008,161 2020-04-10
PCT/US2021/026663 WO2021207659A1 (en) 2020-04-10 2021-04-09 Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1 -yl)phenyl] -6-oxo- 1,6-dihydropyrimidin- 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.02·6] octadeca- 1(18), 2(6), 4, 14, 16-pentaen-8-one

Publications (1)

Publication Number Publication Date
KR20230008742A true KR20230008742A (ko) 2023-01-16

Family

ID=75690727

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227039277A Pending KR20230008742A (ko) 2020-04-10 2021-04-09 (9r,135s)-13-{4-[5-클로로-2-(4-클로로-1h,2,3-트리아졸-1-일)페닐]-6-옥소-1,6-디히드로피리미딘-1-일}-3-(디플루오로메틸)-9-메틸-3,4,7,15-테트라아자트리시클로[12.3.1.02·6]옥타데카-1(18),2(6),4,14,16-펜타엔-8-온의 결정질 형태

Country Status (14)

Country Link
US (1) US20230151010A1 (https=)
EP (1) EP4132930A1 (https=)
JP (2) JP2023521411A (https=)
KR (1) KR20230008742A (https=)
CN (1) CN115916780A (https=)
AU (1) AU2021253946A1 (https=)
BR (1) BR112022020243A2 (https=)
CA (1) CA3179957A1 (https=)
CL (1) CL2022002786A1 (https=)
CO (1) CO2022016067A2 (https=)
IL (1) IL297206A (https=)
MX (1) MX2022012523A (https=)
PE (1) PE20231071A1 (https=)
WO (1) WO2021207659A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY40381A (es) 2022-08-01 2024-01-31 Janssen Pharmaceutica Nv Uso de milvexian para el tratamiento o la prevención del accidente cerebrovascular isquémico
CN120712076A (zh) 2023-02-06 2025-09-26 百时美施贵宝公司 米尔维仙药物组合物
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116987080A (zh) * 2014-01-31 2023-11-03 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (https=) * 2014-10-01 2018-10-20

Also Published As

Publication number Publication date
PE20231071A1 (es) 2023-07-17
IL297206A (en) 2022-12-01
CA3179957A1 (en) 2021-10-14
JP2026048873A (ja) 2026-03-17
CL2022002786A1 (es) 2023-04-14
CO2022016067A2 (es) 2023-01-26
WO2021207659A1 (en) 2021-10-14
CN115916780A (zh) 2023-04-04
US20230151010A1 (en) 2023-05-18
BR112022020243A2 (pt) 2022-11-22
AU2021253946A1 (en) 2022-12-15
JP2023521411A (ja) 2023-05-24
MX2022012523A (es) 2022-11-07
EP4132930A1 (en) 2023-02-15

Similar Documents

Publication Publication Date Title
US9920034B2 (en) Crystalline forms of a factor XIa inhibitor
EP3102200B1 (en) Therapeutic compounds and compositions
JP2026048873A (ja) （９ｒ，１３ｓ）－１３－｛４－［５－クロロ－２－（４－クロロ－１ｈ－１，２，３－トリアゾール－１－イル）フェニル］－６－オキソ－１，６－ジヒドロピリミジン－１－イル｝－３－（ジフルオロメチル）－９－メチル－３，４，７，１５－テトラアザトリシクロ［１２．３．１．０２，６］オクタデカ－１（１８），２（６），４，１４，１６－ペンタエン－８－オンの結晶体
WO2018118705A1 (en) Therapeutic compounds and compositions
JP7196931B2 (ja) （３ｓ）－３－［２－（６－アミノ－２－フルオロピリジン－３－イル）－４－フルオロ－１ｈ－イミダゾール－５－イル］－７－［５－クロロ－２－（１ｈ－テトラゾール－１－イル）フェニル］－２，３－ジヒドロインドリジン－５（１ｈ）－オンの新規結晶
US20080188517A1 (en) Crystalline forms of a factor xa inhibitor
CN116874469B (zh) 一种氧代吡啶类化合物、中间体及其制备方法和用途
KR101852226B1 (ko) 오타믹사반의 벤조산염
US7388096B2 (en) Crystalline forms of a factor Xa inhibitor
CN116947818B (zh) 一种氧代吡啶类化合物、中间体及其制备方法和用途
CN110759901A (zh) 四氢异喹啉类衍生物及其制备方法和用途
KR20210028232A (ko) 옥시피리딘 아미드 유도체의 결정 형태 및 이를 위한 제조 방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902